Persistent Disease Activity Remains a Burden for Patients with Systemic Lupus Erythematosus.

Adult Canada / epidemiology Cross-Sectional Studies Disease Progression Female Follow-Up Studies Humans Linear Models Lupus Erythematosus, Systemic / drug therapy Male Middle Aged Prednisone / therapeutic use Prevalence Prognosis Prospective Studies Severity of Illness Index Young Adult
DISEASE ACTIVITY SYSTEMIC LUPUS ERYTHEMATOSUS

Journal

The Journal of rheumatology
ISSN: 0315-162X
Titre abrégé: J Rheumatol
Pays: Canada
ID NLM: 7501984

Informations de publication

Date de publication:
02 2019
Historique:
accepted: 28 06 2018
pubmed: 17 9 2018
medline: 28 5 2020
entrez: 17 9 2018
Statut: ppublish

Résumé

Persistent systemic lupus erythematosus (SLE) disease activity is associated with increased morbidity and mortality. In a multicenter cohort of patients with prevalent SLE, we described persistence, patterns, and predictors of change in disease activity over time. Based on SLE Disease Activity Index (SLEDAI)-2K scores at cohort entry, patients were classified into 4 groups: low (score < 4; LOW), moderate (4 to < 6; MOD), moderately high (6 to ≤ 10; MHIGH), and very high (> 10; VHIGH). Multivariable linear and longitudinal mixed linear regression models were used to identify predictors of change over time in SLEDAI-2K. There were 2019 participants, with declining followup data over 5 years (1326, 580, 274, 186, and 148 patients, respectively). At cohort entry, mean (± SD) age was 42 (± 17) years, disease duration 11 (± 10) years, and 90% were female. The 4 groups included 44% LOW (n = 891), 20% MOD (n = 400), 22% MHIGH (n = 442), and 14% VHIGH (n = 286); therefore, 36% had clinically important SLE activity. The proportion of patients in the LOW group at entry who moved to a higher activity level varied from 30% (167/557) at 1 year, to 49% (41/83) at 3 years, and 54% (30/56) at 5 years. Among 181 patients with MOD to VHIGH entry activity and 3 years of followup, 116 (64.1%) remained active. In all analyses, only higher SLEDAI-2K at cohort entry remained a significant predictor of higher SLEDAI-2K in subsequent years. Higher SLEDAI-2K at study entry was the single major independent predictor of higher SLEDAI-2K over time, reflecting frequent persistence of active disease, even in patients with longstanding disease. This highlights gaps in the optimal treatment of SLE.

Identifiants

DOI: 10.3899/jrheum.171454 PMID: 30219771
pubmed: 30219771
pii: jrheum.171454
doi: 10.3899/jrheum.171454
doi:

Substances chimiques

Prednisone VB0R961HZT

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

166-175

Auteurs

Christine A Peschken (CA)

From the Departments of Internal Medicine and Community Health Sciences, University of Manitoba, Winnipeg; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec; University of Western Ontario and St. Joseph's Health Care London, London; Hospital for Sick Children, Toronto; University of Toronto, Toronto; Medical Affairs, GlaxoSmithKline Inc., Mississauga, Ontario; CH Maisonneuve-Rosemont, Montreal; BC Children's Hospital, Vancouver, British Columbia; McGill University Health Centre, Montreal, Quebec; Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, Quebec; IWK Health Centre and Dalhousie University, Halifax, Nova Scotia; University of Ottawa, Ottawa, Ontario; Division of Rheumatology, Arthritis Research Canada, University of British Columbia; Rheumatology Clinic, Calgary, Alberta; Montreal Children's Hospital, McGill University Health Centre, Montreal; Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Quebec City, Quebec, Canada; GlaxoSmithKline Inc., King of Prussia, Pennsylvania, USA. christine.peschken@umanitoba.ca.
C.A. Peschken, MD, MSc, FRCPC, Departments of Internal Medicine, and Community Health, University of Manitoba; Y. Wang, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; M. Abrahamowicz, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; J. Pope, MD, University of Western Ontario and St. Joseph's Health Care London; E. Silverman, MD, Hospital for Sick Children, and University of Toronto; A. Sayani, PhD, Medical Affairs, GlaxoSmithKline Inc., Mississauga; S. Iczkovitz, BSc, Medical Affairs, GlaxoSmithKline Inc., Mississauga; J. Ross, MD, GlaxoSmithKline Inc., King of Prussia; M. Zummer, MD, CH Maisonneuve-Rosemont; L. Tucker, MD, BC Children's Hospital; C. Pineau, MD, McGill University Health Centre; D. Levy, MD, Hospital for Sick Children, and University of Toronto; M. Hudson, MD, Jewish General Hospital, Lady Davis Institute and McGill University; C.A. Hitchon, MD, MSc, Department of Internal Medicine, University of Manitoba; A.M. Huber, MD, MSc, IWK Health Centre and Dalhousie University; C.D. Smith, MD, University of Ottawa; A. Avina-Zubieta, MD, PhD, Division of Rheumatology, Arthritis Research Canada, University of British Columbia; H. Arbillaga, MD, Rheumatology Clinic, Calgary; G. Chédeville, MD, Montreal Children's Hospital, McGill University Health Centre; W. Wynant, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; P.R. Fortin, MD, MPH, Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval. christine.peschken@umanitoba.ca.

Yishu Wang (Y)

From the Departments of Internal Medicine and Community Health Sciences, University of Manitoba, Winnipeg; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec; University of Western Ontario and St. Joseph's Health Care London, London; Hospital for Sick Children, Toronto; University of Toronto, Toronto; Medical Affairs, GlaxoSmithKline Inc., Mississauga, Ontario; CH Maisonneuve-Rosemont, Montreal; BC Children's Hospital, Vancouver, British Columbia; McGill University Health Centre, Montreal, Quebec; Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, Quebec; IWK Health Centre and Dalhousie University, Halifax, Nova Scotia; University of Ottawa, Ottawa, Ontario; Division of Rheumatology, Arthritis Research Canada, University of British Columbia; Rheumatology Clinic, Calgary, Alberta; Montreal Children's Hospital, McGill University Health Centre, Montreal; Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Quebec City, Quebec, Canada; GlaxoSmithKline Inc., King of Prussia, Pennsylvania, USA.
C.A. Peschken, MD, MSc, FRCPC, Departments of Internal Medicine, and Community Health, University of Manitoba; Y. Wang, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; M. Abrahamowicz, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; J. Pope, MD, University of Western Ontario and St. Joseph's Health Care London; E. Silverman, MD, Hospital for Sick Children, and University of Toronto; A. Sayani, PhD, Medical Affairs, GlaxoSmithKline Inc., Mississauga; S. Iczkovitz, BSc, Medical Affairs, GlaxoSmithKline Inc., Mississauga; J. Ross, MD, GlaxoSmithKline Inc., King of Prussia; M. Zummer, MD, CH Maisonneuve-Rosemont; L. Tucker, MD, BC Children's Hospital; C. Pineau, MD, McGill University Health Centre; D. Levy, MD, Hospital for Sick Children, and University of Toronto; M. Hudson, MD, Jewish General Hospital, Lady Davis Institute and McGill University; C.A. Hitchon, MD, MSc, Department of Internal Medicine, University of Manitoba; A.M. Huber, MD, MSc, IWK Health Centre and Dalhousie University; C.D. Smith, MD, University of Ottawa; A. Avina-Zubieta, MD, PhD, Division of Rheumatology, Arthritis Research Canada, University of British Columbia; H. Arbillaga, MD, Rheumatology Clinic, Calgary; G. Chédeville, MD, Montreal Children's Hospital, McGill University Health Centre; W. Wynant, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; P.R. Fortin, MD, MPH, Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval.

Michal Abrahamowicz (M)

From the Departments of Internal Medicine and Community Health Sciences, University of Manitoba, Winnipeg; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec; University of Western Ontario and St. Joseph's Health Care London, London; Hospital for Sick Children, Toronto; University of Toronto, Toronto; Medical Affairs, GlaxoSmithKline Inc., Mississauga, Ontario; CH Maisonneuve-Rosemont, Montreal; BC Children's Hospital, Vancouver, British Columbia; McGill University Health Centre, Montreal, Quebec; Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, Quebec; IWK Health Centre and Dalhousie University, Halifax, Nova Scotia; University of Ottawa, Ottawa, Ontario; Division of Rheumatology, Arthritis Research Canada, University of British Columbia; Rheumatology Clinic, Calgary, Alberta; Montreal Children's Hospital, McGill University Health Centre, Montreal; Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Quebec City, Quebec, Canada; GlaxoSmithKline Inc., King of Prussia, Pennsylvania, USA.
C.A. Peschken, MD, MSc, FRCPC, Departments of Internal Medicine, and Community Health, University of Manitoba; Y. Wang, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; M. Abrahamowicz, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; J. Pope, MD, University of Western Ontario and St. Joseph's Health Care London; E. Silverman, MD, Hospital for Sick Children, and University of Toronto; A. Sayani, PhD, Medical Affairs, GlaxoSmithKline Inc., Mississauga; S. Iczkovitz, BSc, Medical Affairs, GlaxoSmithKline Inc., Mississauga; J. Ross, MD, GlaxoSmithKline Inc., King of Prussia; M. Zummer, MD, CH Maisonneuve-Rosemont; L. Tucker, MD, BC Children's Hospital; C. Pineau, MD, McGill University Health Centre; D. Levy, MD, Hospital for Sick Children, and University of Toronto; M. Hudson, MD, Jewish General Hospital, Lady Davis Institute and McGill University; C.A. Hitchon, MD, MSc, Department of Internal Medicine, University of Manitoba; A.M. Huber, MD, MSc, IWK Health Centre and Dalhousie University; C.D. Smith, MD, University of Ottawa; A. Avina-Zubieta, MD, PhD, Division of Rheumatology, Arthritis Research Canada, University of British Columbia; H. Arbillaga, MD, Rheumatology Clinic, Calgary; G. Chédeville, MD, Montreal Children's Hospital, McGill University Health Centre; W. Wynant, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; P.R. Fortin, MD, MPH, Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval.

Janet Pope (J)

From the Departments of Internal Medicine and Community Health Sciences, University of Manitoba, Winnipeg; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec; University of Western Ontario and St. Joseph's Health Care London, London; Hospital for Sick Children, Toronto; University of Toronto, Toronto; Medical Affairs, GlaxoSmithKline Inc., Mississauga, Ontario; CH Maisonneuve-Rosemont, Montreal; BC Children's Hospital, Vancouver, British Columbia; McGill University Health Centre, Montreal, Quebec; Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, Quebec; IWK Health Centre and Dalhousie University, Halifax, Nova Scotia; University of Ottawa, Ottawa, Ontario; Division of Rheumatology, Arthritis Research Canada, University of British Columbia; Rheumatology Clinic, Calgary, Alberta; Montreal Children's Hospital, McGill University Health Centre, Montreal; Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Quebec City, Quebec, Canada; GlaxoSmithKline Inc., King of Prussia, Pennsylvania, USA.
C.A. Peschken, MD, MSc, FRCPC, Departments of Internal Medicine, and Community Health, University of Manitoba; Y. Wang, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; M. Abrahamowicz, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; J. Pope, MD, University of Western Ontario and St. Joseph's Health Care London; E. Silverman, MD, Hospital for Sick Children, and University of Toronto; A. Sayani, PhD, Medical Affairs, GlaxoSmithKline Inc., Mississauga; S. Iczkovitz, BSc, Medical Affairs, GlaxoSmithKline Inc., Mississauga; J. Ross, MD, GlaxoSmithKline Inc., King of Prussia; M. Zummer, MD, CH Maisonneuve-Rosemont; L. Tucker, MD, BC Children's Hospital; C. Pineau, MD, McGill University Health Centre; D. Levy, MD, Hospital for Sick Children, and University of Toronto; M. Hudson, MD, Jewish General Hospital, Lady Davis Institute and McGill University; C.A. Hitchon, MD, MSc, Department of Internal Medicine, University of Manitoba; A.M. Huber, MD, MSc, IWK Health Centre and Dalhousie University; C.D. Smith, MD, University of Ottawa; A. Avina-Zubieta, MD, PhD, Division of Rheumatology, Arthritis Research Canada, University of British Columbia; H. Arbillaga, MD, Rheumatology Clinic, Calgary; G. Chédeville, MD, Montreal Children's Hospital, McGill University Health Centre; W. Wynant, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; P.R. Fortin, MD, MPH, Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval.

Earl Silverman (E)

From the Departments of Internal Medicine and Community Health Sciences, University of Manitoba, Winnipeg; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec; University of Western Ontario and St. Joseph's Health Care London, London; Hospital for Sick Children, Toronto; University of Toronto, Toronto; Medical Affairs, GlaxoSmithKline Inc., Mississauga, Ontario; CH Maisonneuve-Rosemont, Montreal; BC Children's Hospital, Vancouver, British Columbia; McGill University Health Centre, Montreal, Quebec; Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, Quebec; IWK Health Centre and Dalhousie University, Halifax, Nova Scotia; University of Ottawa, Ottawa, Ontario; Division of Rheumatology, Arthritis Research Canada, University of British Columbia; Rheumatology Clinic, Calgary, Alberta; Montreal Children's Hospital, McGill University Health Centre, Montreal; Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Quebec City, Quebec, Canada; GlaxoSmithKline Inc., King of Prussia, Pennsylvania, USA.
C.A. Peschken, MD, MSc, FRCPC, Departments of Internal Medicine, and Community Health, University of Manitoba; Y. Wang, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; M. Abrahamowicz, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; J. Pope, MD, University of Western Ontario and St. Joseph's Health Care London; E. Silverman, MD, Hospital for Sick Children, and University of Toronto; A. Sayani, PhD, Medical Affairs, GlaxoSmithKline Inc., Mississauga; S. Iczkovitz, BSc, Medical Affairs, GlaxoSmithKline Inc., Mississauga; J. Ross, MD, GlaxoSmithKline Inc., King of Prussia; M. Zummer, MD, CH Maisonneuve-Rosemont; L. Tucker, MD, BC Children's Hospital; C. Pineau, MD, McGill University Health Centre; D. Levy, MD, Hospital for Sick Children, and University of Toronto; M. Hudson, MD, Jewish General Hospital, Lady Davis Institute and McGill University; C.A. Hitchon, MD, MSc, Department of Internal Medicine, University of Manitoba; A.M. Huber, MD, MSc, IWK Health Centre and Dalhousie University; C.D. Smith, MD, University of Ottawa; A. Avina-Zubieta, MD, PhD, Division of Rheumatology, Arthritis Research Canada, University of British Columbia; H. Arbillaga, MD, Rheumatology Clinic, Calgary; G. Chédeville, MD, Montreal Children's Hospital, McGill University Health Centre; W. Wynant, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; P.R. Fortin, MD, MPH, Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval.

Amyn Sayani (A)

From the Departments of Internal Medicine and Community Health Sciences, University of Manitoba, Winnipeg; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec; University of Western Ontario and St. Joseph's Health Care London, London; Hospital for Sick Children, Toronto; University of Toronto, Toronto; Medical Affairs, GlaxoSmithKline Inc., Mississauga, Ontario; CH Maisonneuve-Rosemont, Montreal; BC Children's Hospital, Vancouver, British Columbia; McGill University Health Centre, Montreal, Quebec; Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, Quebec; IWK Health Centre and Dalhousie University, Halifax, Nova Scotia; University of Ottawa, Ottawa, Ontario; Division of Rheumatology, Arthritis Research Canada, University of British Columbia; Rheumatology Clinic, Calgary, Alberta; Montreal Children's Hospital, McGill University Health Centre, Montreal; Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Quebec City, Quebec, Canada; GlaxoSmithKline Inc., King of Prussia, Pennsylvania, USA.
C.A. Peschken, MD, MSc, FRCPC, Departments of Internal Medicine, and Community Health, University of Manitoba; Y. Wang, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; M. Abrahamowicz, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; J. Pope, MD, University of Western Ontario and St. Joseph's Health Care London; E. Silverman, MD, Hospital for Sick Children, and University of Toronto; A. Sayani, PhD, Medical Affairs, GlaxoSmithKline Inc., Mississauga; S. Iczkovitz, BSc, Medical Affairs, GlaxoSmithKline Inc., Mississauga; J. Ross, MD, GlaxoSmithKline Inc., King of Prussia; M. Zummer, MD, CH Maisonneuve-Rosemont; L. Tucker, MD, BC Children's Hospital; C. Pineau, MD, McGill University Health Centre; D. Levy, MD, Hospital for Sick Children, and University of Toronto; M. Hudson, MD, Jewish General Hospital, Lady Davis Institute and McGill University; C.A. Hitchon, MD, MSc, Department of Internal Medicine, University of Manitoba; A.M. Huber, MD, MSc, IWK Health Centre and Dalhousie University; C.D. Smith, MD, University of Ottawa; A. Avina-Zubieta, MD, PhD, Division of Rheumatology, Arthritis Research Canada, University of British Columbia; H. Arbillaga, MD, Rheumatology Clinic, Calgary; G. Chédeville, MD, Montreal Children's Hospital, McGill University Health Centre; W. Wynant, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; P.R. Fortin, MD, MPH, Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval.

Sandra Iczkovitz (S)

From the Departments of Internal Medicine and Community Health Sciences, University of Manitoba, Winnipeg; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec; University of Western Ontario and St. Joseph's Health Care London, London; Hospital for Sick Children, Toronto; University of Toronto, Toronto; Medical Affairs, GlaxoSmithKline Inc., Mississauga, Ontario; CH Maisonneuve-Rosemont, Montreal; BC Children's Hospital, Vancouver, British Columbia; McGill University Health Centre, Montreal, Quebec; Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, Quebec; IWK Health Centre and Dalhousie University, Halifax, Nova Scotia; University of Ottawa, Ottawa, Ontario; Division of Rheumatology, Arthritis Research Canada, University of British Columbia; Rheumatology Clinic, Calgary, Alberta; Montreal Children's Hospital, McGill University Health Centre, Montreal; Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Quebec City, Quebec, Canada; GlaxoSmithKline Inc., King of Prussia, Pennsylvania, USA.
C.A. Peschken, MD, MSc, FRCPC, Departments of Internal Medicine, and Community Health, University of Manitoba; Y. Wang, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; M. Abrahamowicz, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; J. Pope, MD, University of Western Ontario and St. Joseph's Health Care London; E. Silverman, MD, Hospital for Sick Children, and University of Toronto; A. Sayani, PhD, Medical Affairs, GlaxoSmithKline Inc., Mississauga; S. Iczkovitz, BSc, Medical Affairs, GlaxoSmithKline Inc., Mississauga; J. Ross, MD, GlaxoSmithKline Inc., King of Prussia; M. Zummer, MD, CH Maisonneuve-Rosemont; L. Tucker, MD, BC Children's Hospital; C. Pineau, MD, McGill University Health Centre; D. Levy, MD, Hospital for Sick Children, and University of Toronto; M. Hudson, MD, Jewish General Hospital, Lady Davis Institute and McGill University; C.A. Hitchon, MD, MSc, Department of Internal Medicine, University of Manitoba; A.M. Huber, MD, MSc, IWK Health Centre and Dalhousie University; C.D. Smith, MD, University of Ottawa; A. Avina-Zubieta, MD, PhD, Division of Rheumatology, Arthritis Research Canada, University of British Columbia; H. Arbillaga, MD, Rheumatology Clinic, Calgary; G. Chédeville, MD, Montreal Children's Hospital, McGill University Health Centre; W. Wynant, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; P.R. Fortin, MD, MPH, Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval.

Jorge Ross (J)

From the Departments of Internal Medicine and Community Health Sciences, University of Manitoba, Winnipeg; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec; University of Western Ontario and St. Joseph's Health Care London, London; Hospital for Sick Children, Toronto; University of Toronto, Toronto; Medical Affairs, GlaxoSmithKline Inc., Mississauga, Ontario; CH Maisonneuve-Rosemont, Montreal; BC Children's Hospital, Vancouver, British Columbia; McGill University Health Centre, Montreal, Quebec; Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, Quebec; IWK Health Centre and Dalhousie University, Halifax, Nova Scotia; University of Ottawa, Ottawa, Ontario; Division of Rheumatology, Arthritis Research Canada, University of British Columbia; Rheumatology Clinic, Calgary, Alberta; Montreal Children's Hospital, McGill University Health Centre, Montreal; Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Quebec City, Quebec, Canada; GlaxoSmithKline Inc., King of Prussia, Pennsylvania, USA.
C.A. Peschken, MD, MSc, FRCPC, Departments of Internal Medicine, and Community Health, University of Manitoba; Y. Wang, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; M. Abrahamowicz, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; J. Pope, MD, University of Western Ontario and St. Joseph's Health Care London; E. Silverman, MD, Hospital for Sick Children, and University of Toronto; A. Sayani, PhD, Medical Affairs, GlaxoSmithKline Inc., Mississauga; S. Iczkovitz, BSc, Medical Affairs, GlaxoSmithKline Inc., Mississauga; J. Ross, MD, GlaxoSmithKline Inc., King of Prussia; M. Zummer, MD, CH Maisonneuve-Rosemont; L. Tucker, MD, BC Children's Hospital; C. Pineau, MD, McGill University Health Centre; D. Levy, MD, Hospital for Sick Children, and University of Toronto; M. Hudson, MD, Jewish General Hospital, Lady Davis Institute and McGill University; C.A. Hitchon, MD, MSc, Department of Internal Medicine, University of Manitoba; A.M. Huber, MD, MSc, IWK Health Centre and Dalhousie University; C.D. Smith, MD, University of Ottawa; A. Avina-Zubieta, MD, PhD, Division of Rheumatology, Arthritis Research Canada, University of British Columbia; H. Arbillaga, MD, Rheumatology Clinic, Calgary; G. Chédeville, MD, Montreal Children's Hospital, McGill University Health Centre; W. Wynant, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; P.R. Fortin, MD, MPH, Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval.

Michel Zummer (M)

From the Departments of Internal Medicine and Community Health Sciences, University of Manitoba, Winnipeg; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec; University of Western Ontario and St. Joseph's Health Care London, London; Hospital for Sick Children, Toronto; University of Toronto, Toronto; Medical Affairs, GlaxoSmithKline Inc., Mississauga, Ontario; CH Maisonneuve-Rosemont, Montreal; BC Children's Hospital, Vancouver, British Columbia; McGill University Health Centre, Montreal, Quebec; Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, Quebec; IWK Health Centre and Dalhousie University, Halifax, Nova Scotia; University of Ottawa, Ottawa, Ontario; Division of Rheumatology, Arthritis Research Canada, University of British Columbia; Rheumatology Clinic, Calgary, Alberta; Montreal Children's Hospital, McGill University Health Centre, Montreal; Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Quebec City, Quebec, Canada; GlaxoSmithKline Inc., King of Prussia, Pennsylvania, USA.
C.A. Peschken, MD, MSc, FRCPC, Departments of Internal Medicine, and Community Health, University of Manitoba; Y. Wang, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; M. Abrahamowicz, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; J. Pope, MD, University of Western Ontario and St. Joseph's Health Care London; E. Silverman, MD, Hospital for Sick Children, and University of Toronto; A. Sayani, PhD, Medical Affairs, GlaxoSmithKline Inc., Mississauga; S. Iczkovitz, BSc, Medical Affairs, GlaxoSmithKline Inc., Mississauga; J. Ross, MD, GlaxoSmithKline Inc., King of Prussia; M. Zummer, MD, CH Maisonneuve-Rosemont; L. Tucker, MD, BC Children's Hospital; C. Pineau, MD, McGill University Health Centre; D. Levy, MD, Hospital for Sick Children, and University of Toronto; M. Hudson, MD, Jewish General Hospital, Lady Davis Institute and McGill University; C.A. Hitchon, MD, MSc, Department of Internal Medicine, University of Manitoba; A.M. Huber, MD, MSc, IWK Health Centre and Dalhousie University; C.D. Smith, MD, University of Ottawa; A. Avina-Zubieta, MD, PhD, Division of Rheumatology, Arthritis Research Canada, University of British Columbia; H. Arbillaga, MD, Rheumatology Clinic, Calgary; G. Chédeville, MD, Montreal Children's Hospital, McGill University Health Centre; W. Wynant, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; P.R. Fortin, MD, MPH, Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval.

Lori Tucker (L)

From the Departments of Internal Medicine and Community Health Sciences, University of Manitoba, Winnipeg; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec; University of Western Ontario and St. Joseph's Health Care London, London; Hospital for Sick Children, Toronto; University of Toronto, Toronto; Medical Affairs, GlaxoSmithKline Inc., Mississauga, Ontario; CH Maisonneuve-Rosemont, Montreal; BC Children's Hospital, Vancouver, British Columbia; McGill University Health Centre, Montreal, Quebec; Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, Quebec; IWK Health Centre and Dalhousie University, Halifax, Nova Scotia; University of Ottawa, Ottawa, Ontario; Division of Rheumatology, Arthritis Research Canada, University of British Columbia; Rheumatology Clinic, Calgary, Alberta; Montreal Children's Hospital, McGill University Health Centre, Montreal; Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Quebec City, Quebec, Canada; GlaxoSmithKline Inc., King of Prussia, Pennsylvania, USA.
C.A. Peschken, MD, MSc, FRCPC, Departments of Internal Medicine, and Community Health, University of Manitoba; Y. Wang, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; M. Abrahamowicz, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; J. Pope, MD, University of Western Ontario and St. Joseph's Health Care London; E. Silverman, MD, Hospital for Sick Children, and University of Toronto; A. Sayani, PhD, Medical Affairs, GlaxoSmithKline Inc., Mississauga; S. Iczkovitz, BSc, Medical Affairs, GlaxoSmithKline Inc., Mississauga; J. Ross, MD, GlaxoSmithKline Inc., King of Prussia; M. Zummer, MD, CH Maisonneuve-Rosemont; L. Tucker, MD, BC Children's Hospital; C. Pineau, MD, McGill University Health Centre; D. Levy, MD, Hospital for Sick Children, and University of Toronto; M. Hudson, MD, Jewish General Hospital, Lady Davis Institute and McGill University; C.A. Hitchon, MD, MSc, Department of Internal Medicine, University of Manitoba; A.M. Huber, MD, MSc, IWK Health Centre and Dalhousie University; C.D. Smith, MD, University of Ottawa; A. Avina-Zubieta, MD, PhD, Division of Rheumatology, Arthritis Research Canada, University of British Columbia; H. Arbillaga, MD, Rheumatology Clinic, Calgary; G. Chédeville, MD, Montreal Children's Hospital, McGill University Health Centre; W. Wynant, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; P.R. Fortin, MD, MPH, Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval.

Christian Pineau (C)

From the Departments of Internal Medicine and Community Health Sciences, University of Manitoba, Winnipeg; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec; University of Western Ontario and St. Joseph's Health Care London, London; Hospital for Sick Children, Toronto; University of Toronto, Toronto; Medical Affairs, GlaxoSmithKline Inc., Mississauga, Ontario; CH Maisonneuve-Rosemont, Montreal; BC Children's Hospital, Vancouver, British Columbia; McGill University Health Centre, Montreal, Quebec; Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, Quebec; IWK Health Centre and Dalhousie University, Halifax, Nova Scotia; University of Ottawa, Ottawa, Ontario; Division of Rheumatology, Arthritis Research Canada, University of British Columbia; Rheumatology Clinic, Calgary, Alberta; Montreal Children's Hospital, McGill University Health Centre, Montreal; Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Quebec City, Quebec, Canada; GlaxoSmithKline Inc., King of Prussia, Pennsylvania, USA.
C.A. Peschken, MD, MSc, FRCPC, Departments of Internal Medicine, and Community Health, University of Manitoba; Y. Wang, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; M. Abrahamowicz, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; J. Pope, MD, University of Western Ontario and St. Joseph's Health Care London; E. Silverman, MD, Hospital for Sick Children, and University of Toronto; A. Sayani, PhD, Medical Affairs, GlaxoSmithKline Inc., Mississauga; S. Iczkovitz, BSc, Medical Affairs, GlaxoSmithKline Inc., Mississauga; J. Ross, MD, GlaxoSmithKline Inc., King of Prussia; M. Zummer, MD, CH Maisonneuve-Rosemont; L. Tucker, MD, BC Children's Hospital; C. Pineau, MD, McGill University Health Centre; D. Levy, MD, Hospital for Sick Children, and University of Toronto; M. Hudson, MD, Jewish General Hospital, Lady Davis Institute and McGill University; C.A. Hitchon, MD, MSc, Department of Internal Medicine, University of Manitoba; A.M. Huber, MD, MSc, IWK Health Centre and Dalhousie University; C.D. Smith, MD, University of Ottawa; A. Avina-Zubieta, MD, PhD, Division of Rheumatology, Arthritis Research Canada, University of British Columbia; H. Arbillaga, MD, Rheumatology Clinic, Calgary; G. Chédeville, MD, Montreal Children's Hospital, McGill University Health Centre; W. Wynant, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; P.R. Fortin, MD, MPH, Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval.

Deborah Levy (D)

From the Departments of Internal Medicine and Community Health Sciences, University of Manitoba, Winnipeg; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec; University of Western Ontario and St. Joseph's Health Care London, London; Hospital for Sick Children, Toronto; University of Toronto, Toronto; Medical Affairs, GlaxoSmithKline Inc., Mississauga, Ontario; CH Maisonneuve-Rosemont, Montreal; BC Children's Hospital, Vancouver, British Columbia; McGill University Health Centre, Montreal, Quebec; Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, Quebec; IWK Health Centre and Dalhousie University, Halifax, Nova Scotia; University of Ottawa, Ottawa, Ontario; Division of Rheumatology, Arthritis Research Canada, University of British Columbia; Rheumatology Clinic, Calgary, Alberta; Montreal Children's Hospital, McGill University Health Centre, Montreal; Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Quebec City, Quebec, Canada; GlaxoSmithKline Inc., King of Prussia, Pennsylvania, USA.
C.A. Peschken, MD, MSc, FRCPC, Departments of Internal Medicine, and Community Health, University of Manitoba; Y. Wang, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; M. Abrahamowicz, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; J. Pope, MD, University of Western Ontario and St. Joseph's Health Care London; E. Silverman, MD, Hospital for Sick Children, and University of Toronto; A. Sayani, PhD, Medical Affairs, GlaxoSmithKline Inc., Mississauga; S. Iczkovitz, BSc, Medical Affairs, GlaxoSmithKline Inc., Mississauga; J. Ross, MD, GlaxoSmithKline Inc., King of Prussia; M. Zummer, MD, CH Maisonneuve-Rosemont; L. Tucker, MD, BC Children's Hospital; C. Pineau, MD, McGill University Health Centre; D. Levy, MD, Hospital for Sick Children, and University of Toronto; M. Hudson, MD, Jewish General Hospital, Lady Davis Institute and McGill University; C.A. Hitchon, MD, MSc, Department of Internal Medicine, University of Manitoba; A.M. Huber, MD, MSc, IWK Health Centre and Dalhousie University; C.D. Smith, MD, University of Ottawa; A. Avina-Zubieta, MD, PhD, Division of Rheumatology, Arthritis Research Canada, University of British Columbia; H. Arbillaga, MD, Rheumatology Clinic, Calgary; G. Chédeville, MD, Montreal Children's Hospital, McGill University Health Centre; W. Wynant, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; P.R. Fortin, MD, MPH, Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval.

Marie Hudson (M)

From the Departments of Internal Medicine and Community Health Sciences, University of Manitoba, Winnipeg; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec; University of Western Ontario and St. Joseph's Health Care London, London; Hospital for Sick Children, Toronto; University of Toronto, Toronto; Medical Affairs, GlaxoSmithKline Inc., Mississauga, Ontario; CH Maisonneuve-Rosemont, Montreal; BC Children's Hospital, Vancouver, British Columbia; McGill University Health Centre, Montreal, Quebec; Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, Quebec; IWK Health Centre and Dalhousie University, Halifax, Nova Scotia; University of Ottawa, Ottawa, Ontario; Division of Rheumatology, Arthritis Research Canada, University of British Columbia; Rheumatology Clinic, Calgary, Alberta; Montreal Children's Hospital, McGill University Health Centre, Montreal; Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Quebec City, Quebec, Canada; GlaxoSmithKline Inc., King of Prussia, Pennsylvania, USA.
C.A. Peschken, MD, MSc, FRCPC, Departments of Internal Medicine, and Community Health, University of Manitoba; Y. Wang, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; M. Abrahamowicz, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; J. Pope, MD, University of Western Ontario and St. Joseph's Health Care London; E. Silverman, MD, Hospital for Sick Children, and University of Toronto; A. Sayani, PhD, Medical Affairs, GlaxoSmithKline Inc., Mississauga; S. Iczkovitz, BSc, Medical Affairs, GlaxoSmithKline Inc., Mississauga; J. Ross, MD, GlaxoSmithKline Inc., King of Prussia; M. Zummer, MD, CH Maisonneuve-Rosemont; L. Tucker, MD, BC Children's Hospital; C. Pineau, MD, McGill University Health Centre; D. Levy, MD, Hospital for Sick Children, and University of Toronto; M. Hudson, MD, Jewish General Hospital, Lady Davis Institute and McGill University; C.A. Hitchon, MD, MSc, Department of Internal Medicine, University of Manitoba; A.M. Huber, MD, MSc, IWK Health Centre and Dalhousie University; C.D. Smith, MD, University of Ottawa; A. Avina-Zubieta, MD, PhD, Division of Rheumatology, Arthritis Research Canada, University of British Columbia; H. Arbillaga, MD, Rheumatology Clinic, Calgary; G. Chédeville, MD, Montreal Children's Hospital, McGill University Health Centre; W. Wynant, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; P.R. Fortin, MD, MPH, Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval.

Carol A Hitchon (CA)

From the Departments of Internal Medicine and Community Health Sciences, University of Manitoba, Winnipeg; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec; University of Western Ontario and St. Joseph's Health Care London, London; Hospital for Sick Children, Toronto; University of Toronto, Toronto; Medical Affairs, GlaxoSmithKline Inc., Mississauga, Ontario; CH Maisonneuve-Rosemont, Montreal; BC Children's Hospital, Vancouver, British Columbia; McGill University Health Centre, Montreal, Quebec; Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, Quebec; IWK Health Centre and Dalhousie University, Halifax, Nova Scotia; University of Ottawa, Ottawa, Ontario; Division of Rheumatology, Arthritis Research Canada, University of British Columbia; Rheumatology Clinic, Calgary, Alberta; Montreal Children's Hospital, McGill University Health Centre, Montreal; Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Quebec City, Quebec, Canada; GlaxoSmithKline Inc., King of Prussia, Pennsylvania, USA.
C.A. Peschken, MD, MSc, FRCPC, Departments of Internal Medicine, and Community Health, University of Manitoba; Y. Wang, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; M. Abrahamowicz, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; J. Pope, MD, University of Western Ontario and St. Joseph's Health Care London; E. Silverman, MD, Hospital for Sick Children, and University of Toronto; A. Sayani, PhD, Medical Affairs, GlaxoSmithKline Inc., Mississauga; S. Iczkovitz, BSc, Medical Affairs, GlaxoSmithKline Inc., Mississauga; J. Ross, MD, GlaxoSmithKline Inc., King of Prussia; M. Zummer, MD, CH Maisonneuve-Rosemont; L. Tucker, MD, BC Children's Hospital; C. Pineau, MD, McGill University Health Centre; D. Levy, MD, Hospital for Sick Children, and University of Toronto; M. Hudson, MD, Jewish General Hospital, Lady Davis Institute and McGill University; C.A. Hitchon, MD, MSc, Department of Internal Medicine, University of Manitoba; A.M. Huber, MD, MSc, IWK Health Centre and Dalhousie University; C.D. Smith, MD, University of Ottawa; A. Avina-Zubieta, MD, PhD, Division of Rheumatology, Arthritis Research Canada, University of British Columbia; H. Arbillaga, MD, Rheumatology Clinic, Calgary; G. Chédeville, MD, Montreal Children's Hospital, McGill University Health Centre; W. Wynant, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; P.R. Fortin, MD, MPH, Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval.

Adam M Huber (AM)

From the Departments of Internal Medicine and Community Health Sciences, University of Manitoba, Winnipeg; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec; University of Western Ontario and St. Joseph's Health Care London, London; Hospital for Sick Children, Toronto; University of Toronto, Toronto; Medical Affairs, GlaxoSmithKline Inc., Mississauga, Ontario; CH Maisonneuve-Rosemont, Montreal; BC Children's Hospital, Vancouver, British Columbia; McGill University Health Centre, Montreal, Quebec; Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, Quebec; IWK Health Centre and Dalhousie University, Halifax, Nova Scotia; University of Ottawa, Ottawa, Ontario; Division of Rheumatology, Arthritis Research Canada, University of British Columbia; Rheumatology Clinic, Calgary, Alberta; Montreal Children's Hospital, McGill University Health Centre, Montreal; Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Quebec City, Quebec, Canada; GlaxoSmithKline Inc., King of Prussia, Pennsylvania, USA.
C.A. Peschken, MD, MSc, FRCPC, Departments of Internal Medicine, and Community Health, University of Manitoba; Y. Wang, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; M. Abrahamowicz, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; J. Pope, MD, University of Western Ontario and St. Joseph's Health Care London; E. Silverman, MD, Hospital for Sick Children, and University of Toronto; A. Sayani, PhD, Medical Affairs, GlaxoSmithKline Inc., Mississauga; S. Iczkovitz, BSc, Medical Affairs, GlaxoSmithKline Inc., Mississauga; J. Ross, MD, GlaxoSmithKline Inc., King of Prussia; M. Zummer, MD, CH Maisonneuve-Rosemont; L. Tucker, MD, BC Children's Hospital; C. Pineau, MD, McGill University Health Centre; D. Levy, MD, Hospital for Sick Children, and University of Toronto; M. Hudson, MD, Jewish General Hospital, Lady Davis Institute and McGill University; C.A. Hitchon, MD, MSc, Department of Internal Medicine, University of Manitoba; A.M. Huber, MD, MSc, IWK Health Centre and Dalhousie University; C.D. Smith, MD, University of Ottawa; A. Avina-Zubieta, MD, PhD, Division of Rheumatology, Arthritis Research Canada, University of British Columbia; H. Arbillaga, MD, Rheumatology Clinic, Calgary; G. Chédeville, MD, Montreal Children's Hospital, McGill University Health Centre; W. Wynant, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; P.R. Fortin, MD, MPH, Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval.

C Douglas Smith (CD)

From the Departments of Internal Medicine and Community Health Sciences, University of Manitoba, Winnipeg; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec; University of Western Ontario and St. Joseph's Health Care London, London; Hospital for Sick Children, Toronto; University of Toronto, Toronto; Medical Affairs, GlaxoSmithKline Inc., Mississauga, Ontario; CH Maisonneuve-Rosemont, Montreal; BC Children's Hospital, Vancouver, British Columbia; McGill University Health Centre, Montreal, Quebec; Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, Quebec; IWK Health Centre and Dalhousie University, Halifax, Nova Scotia; University of Ottawa, Ottawa, Ontario; Division of Rheumatology, Arthritis Research Canada, University of British Columbia; Rheumatology Clinic, Calgary, Alberta; Montreal Children's Hospital, McGill University Health Centre, Montreal; Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Quebec City, Quebec, Canada; GlaxoSmithKline Inc., King of Prussia, Pennsylvania, USA.
C.A. Peschken, MD, MSc, FRCPC, Departments of Internal Medicine, and Community Health, University of Manitoba; Y. Wang, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; M. Abrahamowicz, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; J. Pope, MD, University of Western Ontario and St. Joseph's Health Care London; E. Silverman, MD, Hospital for Sick Children, and University of Toronto; A. Sayani, PhD, Medical Affairs, GlaxoSmithKline Inc., Mississauga; S. Iczkovitz, BSc, Medical Affairs, GlaxoSmithKline Inc., Mississauga; J. Ross, MD, GlaxoSmithKline Inc., King of Prussia; M. Zummer, MD, CH Maisonneuve-Rosemont; L. Tucker, MD, BC Children's Hospital; C. Pineau, MD, McGill University Health Centre; D. Levy, MD, Hospital for Sick Children, and University of Toronto; M. Hudson, MD, Jewish General Hospital, Lady Davis Institute and McGill University; C.A. Hitchon, MD, MSc, Department of Internal Medicine, University of Manitoba; A.M. Huber, MD, MSc, IWK Health Centre and Dalhousie University; C.D. Smith, MD, University of Ottawa; A. Avina-Zubieta, MD, PhD, Division of Rheumatology, Arthritis Research Canada, University of British Columbia; H. Arbillaga, MD, Rheumatology Clinic, Calgary; G. Chédeville, MD, Montreal Children's Hospital, McGill University Health Centre; W. Wynant, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; P.R. Fortin, MD, MPH, Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval.

Antonio Avina-Zubieta (A)

From the Departments of Internal Medicine and Community Health Sciences, University of Manitoba, Winnipeg; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec; University of Western Ontario and St. Joseph's Health Care London, London; Hospital for Sick Children, Toronto; University of Toronto, Toronto; Medical Affairs, GlaxoSmithKline Inc., Mississauga, Ontario; CH Maisonneuve-Rosemont, Montreal; BC Children's Hospital, Vancouver, British Columbia; McGill University Health Centre, Montreal, Quebec; Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, Quebec; IWK Health Centre and Dalhousie University, Halifax, Nova Scotia; University of Ottawa, Ottawa, Ontario; Division of Rheumatology, Arthritis Research Canada, University of British Columbia; Rheumatology Clinic, Calgary, Alberta; Montreal Children's Hospital, McGill University Health Centre, Montreal; Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Quebec City, Quebec, Canada; GlaxoSmithKline Inc., King of Prussia, Pennsylvania, USA.
C.A. Peschken, MD, MSc, FRCPC, Departments of Internal Medicine, and Community Health, University of Manitoba; Y. Wang, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; M. Abrahamowicz, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; J. Pope, MD, University of Western Ontario and St. Joseph's Health Care London; E. Silverman, MD, Hospital for Sick Children, and University of Toronto; A. Sayani, PhD, Medical Affairs, GlaxoSmithKline Inc., Mississauga; S. Iczkovitz, BSc, Medical Affairs, GlaxoSmithKline Inc., Mississauga; J. Ross, MD, GlaxoSmithKline Inc., King of Prussia; M. Zummer, MD, CH Maisonneuve-Rosemont; L. Tucker, MD, BC Children's Hospital; C. Pineau, MD, McGill University Health Centre; D. Levy, MD, Hospital for Sick Children, and University of Toronto; M. Hudson, MD, Jewish General Hospital, Lady Davis Institute and McGill University; C.A. Hitchon, MD, MSc, Department of Internal Medicine, University of Manitoba; A.M. Huber, MD, MSc, IWK Health Centre and Dalhousie University; C.D. Smith, MD, University of Ottawa; A. Avina-Zubieta, MD, PhD, Division of Rheumatology, Arthritis Research Canada, University of British Columbia; H. Arbillaga, MD, Rheumatology Clinic, Calgary; G. Chédeville, MD, Montreal Children's Hospital, McGill University Health Centre; W. Wynant, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; P.R. Fortin, MD, MPH, Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval.

Hector Arbillaga (H)

From the Departments of Internal Medicine and Community Health Sciences, University of Manitoba, Winnipeg; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec; University of Western Ontario and St. Joseph's Health Care London, London; Hospital for Sick Children, Toronto; University of Toronto, Toronto; Medical Affairs, GlaxoSmithKline Inc., Mississauga, Ontario; CH Maisonneuve-Rosemont, Montreal; BC Children's Hospital, Vancouver, British Columbia; McGill University Health Centre, Montreal, Quebec; Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, Quebec; IWK Health Centre and Dalhousie University, Halifax, Nova Scotia; University of Ottawa, Ottawa, Ontario; Division of Rheumatology, Arthritis Research Canada, University of British Columbia; Rheumatology Clinic, Calgary, Alberta; Montreal Children's Hospital, McGill University Health Centre, Montreal; Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Quebec City, Quebec, Canada; GlaxoSmithKline Inc., King of Prussia, Pennsylvania, USA.
C.A. Peschken, MD, MSc, FRCPC, Departments of Internal Medicine, and Community Health, University of Manitoba; Y. Wang, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; M. Abrahamowicz, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; J. Pope, MD, University of Western Ontario and St. Joseph's Health Care London; E. Silverman, MD, Hospital for Sick Children, and University of Toronto; A. Sayani, PhD, Medical Affairs, GlaxoSmithKline Inc., Mississauga; S. Iczkovitz, BSc, Medical Affairs, GlaxoSmithKline Inc., Mississauga; J. Ross, MD, GlaxoSmithKline Inc., King of Prussia; M. Zummer, MD, CH Maisonneuve-Rosemont; L. Tucker, MD, BC Children's Hospital; C. Pineau, MD, McGill University Health Centre; D. Levy, MD, Hospital for Sick Children, and University of Toronto; M. Hudson, MD, Jewish General Hospital, Lady Davis Institute and McGill University; C.A. Hitchon, MD, MSc, Department of Internal Medicine, University of Manitoba; A.M. Huber, MD, MSc, IWK Health Centre and Dalhousie University; C.D. Smith, MD, University of Ottawa; A. Avina-Zubieta, MD, PhD, Division of Rheumatology, Arthritis Research Canada, University of British Columbia; H. Arbillaga, MD, Rheumatology Clinic, Calgary; G. Chédeville, MD, Montreal Children's Hospital, McGill University Health Centre; W. Wynant, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; P.R. Fortin, MD, MPH, Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval.

Gaëlle Chédeville (G)

From the Departments of Internal Medicine and Community Health Sciences, University of Manitoba, Winnipeg; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec; University of Western Ontario and St. Joseph's Health Care London, London; Hospital for Sick Children, Toronto; University of Toronto, Toronto; Medical Affairs, GlaxoSmithKline Inc., Mississauga, Ontario; CH Maisonneuve-Rosemont, Montreal; BC Children's Hospital, Vancouver, British Columbia; McGill University Health Centre, Montreal, Quebec; Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, Quebec; IWK Health Centre and Dalhousie University, Halifax, Nova Scotia; University of Ottawa, Ottawa, Ontario; Division of Rheumatology, Arthritis Research Canada, University of British Columbia; Rheumatology Clinic, Calgary, Alberta; Montreal Children's Hospital, McGill University Health Centre, Montreal; Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Quebec City, Quebec, Canada; GlaxoSmithKline Inc., King of Prussia, Pennsylvania, USA.
C.A. Peschken, MD, MSc, FRCPC, Departments of Internal Medicine, and Community Health, University of Manitoba; Y. Wang, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; M. Abrahamowicz, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; J. Pope, MD, University of Western Ontario and St. Joseph's Health Care London; E. Silverman, MD, Hospital for Sick Children, and University of Toronto; A. Sayani, PhD, Medical Affairs, GlaxoSmithKline Inc., Mississauga; S. Iczkovitz, BSc, Medical Affairs, GlaxoSmithKline Inc., Mississauga; J. Ross, MD, GlaxoSmithKline Inc., King of Prussia; M. Zummer, MD, CH Maisonneuve-Rosemont; L. Tucker, MD, BC Children's Hospital; C. Pineau, MD, McGill University Health Centre; D. Levy, MD, Hospital for Sick Children, and University of Toronto; M. Hudson, MD, Jewish General Hospital, Lady Davis Institute and McGill University; C.A. Hitchon, MD, MSc, Department of Internal Medicine, University of Manitoba; A.M. Huber, MD, MSc, IWK Health Centre and Dalhousie University; C.D. Smith, MD, University of Ottawa; A. Avina-Zubieta, MD, PhD, Division of Rheumatology, Arthritis Research Canada, University of British Columbia; H. Arbillaga, MD, Rheumatology Clinic, Calgary; G. Chédeville, MD, Montreal Children's Hospital, McGill University Health Centre; W. Wynant, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; P.R. Fortin, MD, MPH, Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval.

Willy Wynant (W)

From the Departments of Internal Medicine and Community Health Sciences, University of Manitoba, Winnipeg; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec; University of Western Ontario and St. Joseph's Health Care London, London; Hospital for Sick Children, Toronto; University of Toronto, Toronto; Medical Affairs, GlaxoSmithKline Inc., Mississauga, Ontario; CH Maisonneuve-Rosemont, Montreal; BC Children's Hospital, Vancouver, British Columbia; McGill University Health Centre, Montreal, Quebec; Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, Quebec; IWK Health Centre and Dalhousie University, Halifax, Nova Scotia; University of Ottawa, Ottawa, Ontario; Division of Rheumatology, Arthritis Research Canada, University of British Columbia; Rheumatology Clinic, Calgary, Alberta; Montreal Children's Hospital, McGill University Health Centre, Montreal; Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Quebec City, Quebec, Canada; GlaxoSmithKline Inc., King of Prussia, Pennsylvania, USA.
C.A. Peschken, MD, MSc, FRCPC, Departments of Internal Medicine, and Community Health, University of Manitoba; Y. Wang, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; M. Abrahamowicz, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; J. Pope, MD, University of Western Ontario and St. Joseph's Health Care London; E. Silverman, MD, Hospital for Sick Children, and University of Toronto; A. Sayani, PhD, Medical Affairs, GlaxoSmithKline Inc., Mississauga; S. Iczkovitz, BSc, Medical Affairs, GlaxoSmithKline Inc., Mississauga; J. Ross, MD, GlaxoSmithKline Inc., King of Prussia; M. Zummer, MD, CH Maisonneuve-Rosemont; L. Tucker, MD, BC Children's Hospital; C. Pineau, MD, McGill University Health Centre; D. Levy, MD, Hospital for Sick Children, and University of Toronto; M. Hudson, MD, Jewish General Hospital, Lady Davis Institute and McGill University; C.A. Hitchon, MD, MSc, Department of Internal Medicine, University of Manitoba; A.M. Huber, MD, MSc, IWK Health Centre and Dalhousie University; C.D. Smith, MD, University of Ottawa; A. Avina-Zubieta, MD, PhD, Division of Rheumatology, Arthritis Research Canada, University of British Columbia; H. Arbillaga, MD, Rheumatology Clinic, Calgary; G. Chédeville, MD, Montreal Children's Hospital, McGill University Health Centre; W. Wynant, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; P.R. Fortin, MD, MPH, Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval.

Paul R Fortin (PR)

From the Departments of Internal Medicine and Community Health Sciences, University of Manitoba, Winnipeg; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec; University of Western Ontario and St. Joseph's Health Care London, London; Hospital for Sick Children, Toronto; University of Toronto, Toronto; Medical Affairs, GlaxoSmithKline Inc., Mississauga, Ontario; CH Maisonneuve-Rosemont, Montreal; BC Children's Hospital, Vancouver, British Columbia; McGill University Health Centre, Montreal, Quebec; Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, Quebec; IWK Health Centre and Dalhousie University, Halifax, Nova Scotia; University of Ottawa, Ottawa, Ontario; Division of Rheumatology, Arthritis Research Canada, University of British Columbia; Rheumatology Clinic, Calgary, Alberta; Montreal Children's Hospital, McGill University Health Centre, Montreal; Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Quebec City, Quebec, Canada; GlaxoSmithKline Inc., King of Prussia, Pennsylvania, USA.
C.A. Peschken, MD, MSc, FRCPC, Departments of Internal Medicine, and Community Health, University of Manitoba; Y. Wang, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; M. Abrahamowicz, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; J. Pope, MD, University of Western Ontario and St. Joseph's Health Care London; E. Silverman, MD, Hospital for Sick Children, and University of Toronto; A. Sayani, PhD, Medical Affairs, GlaxoSmithKline Inc., Mississauga; S. Iczkovitz, BSc, Medical Affairs, GlaxoSmithKline Inc., Mississauga; J. Ross, MD, GlaxoSmithKline Inc., King of Prussia; M. Zummer, MD, CH Maisonneuve-Rosemont; L. Tucker, MD, BC Children's Hospital; C. Pineau, MD, McGill University Health Centre; D. Levy, MD, Hospital for Sick Children, and University of Toronto; M. Hudson, MD, Jewish General Hospital, Lady Davis Institute and McGill University; C.A. Hitchon, MD, MSc, Department of Internal Medicine, University of Manitoba; A.M. Huber, MD, MSc, IWK Health Centre and Dalhousie University; C.D. Smith, MD, University of Ottawa; A. Avina-Zubieta, MD, PhD, Division of Rheumatology, Arthritis Research Canada, University of British Columbia; H. Arbillaga, MD, Rheumatology Clinic, Calgary; G. Chédeville, MD, Montreal Children's Hospital, McGill University Health Centre; W. Wynant, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; P.R. Fortin, MD, MPH, Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Persistent Disease Activity Remains a Burden...
questionsmedicales.fr › Régions géographiques › Amériques › Amérique du Nord › Canada › Persistent Disease Activity Remains a Burden...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études transversales › Persistent Disease Activity Remains a Burden...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Évolution de la maladie › Persistent Disease Activity Remains a Burden...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études de suivi › Persistent Disease Activity Remains a Burden...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Persistent Disease Activity Remains a Burden...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de régression › Modèles linéaires › Persistent Disease Activity Remains a Burden...
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Lupus érythémateux disséminé › Persistent Disease Activity Remains a Burden...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Persistent Disease Activity Remains a Burden...
questionsmedicales.fr › Composés polycycliques › Composés à cycles fusionnés › Stéroïdes › Prégnanes › Prégnadiènes › Prégnadiènediols › Prednisone › Persistent Disease Activity Remains a Burden...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Morbidité › Prévalence › Persistent Disease Activity Remains a Burden...
questionsmedicales.fr › Diagnostic › Pronostic › Persistent Disease Activity Remains a Burden...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › Persistent Disease Activity Remains a Burden...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Enquêtes et questionnaires › Enquêtes de santé › Indicateurs d'état de santé › Acuité des besoins du patient › Indice de gravité de la maladie › Persistent Disease Activity Remains a Burden...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Jeune adulte › Persistent Disease Activity Remains a Burden...